Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Cuts Workforce

709

Dallas, Texas 02/13/2014 (FINANCIALSTRENDS) – Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has since announced that it will make some drastic changes in the company. First change is Dr. Sands, who will continue till a successor is chosen by the management, with conditional resignation in place. This move is as expected considering the fact that this company, under Dr. Sands leadership, has been looking for a partner is the diabetes line, for over two years now! The LX4211 which is already in late-stage testing for diabetes has yet to find the suitable partner to move things forward.

Halves workforce

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) sudden move also includes cutting back on its work force by nearly half, or 45% exactly. The reason for reworking the strength of the work force is to bring in better liquidity to the common. In 2013, the company will make a saving of nearly $14 million, which by next year is expected to be quite substantial, at $22 million; considering that it currently holds $150 million in funds.

The company needs more funding now that it has decided to stop work on two of its early-stage development stage drugs and instead concentrate on its signature twin drugs, which are in very late stage of development.

Apparently, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) does not require that much a work force to concentrate entirely on the development of its LX4211.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) had failed to see good results with – LX1033 which was for treating ulcerative colitis.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will now focus on telotristat etiprate in carcinoid syndrome as well as LX4211 which is expected to treat both types of diabetes- Type 1 and Type 2.

The tough part for Lexicon at this stage is that most competitors are already in position in diabetes and SGLT-1/2market. Where, Jonhnson and Johson will have Invokana and Astrazenca will have Farxiga, with Lilly and Astellas to soon bring-up the rare, in a period less than five years.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.